162. Pemphigoid Clinical trials / Disease details

Clinical trials : 90 / Drugs : 122 - (DrugBank : 47) / Drug target genes : 34 - Drug target pathways : 144

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05263505 (ClinicalTrials.gov)	February 21, 2022	16/2/2022	Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid	Baricitinib for the Treatment of Ocular Mucous Membrane Pemphigoid	Mucous Membrane Pemphigoid;Cicatrizing Conjunctivitis	Drug: Baricitinib 2 MG [Olumiant];Drug: Methotrexate;Drug: Azathioprine;Drug: Mycophenolate	Washington University School of Medicine	Eli Lilly and Company	Recruiting	18 Years	N/A	All	20	Phase 2	United States
2	NCT04744623 (ClinicalTrials.gov)	September 30, 2020	2/2/2021	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone	Benign Mucous Membrane Pemphigoid	Drug: large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP	Tanta University	NULL	Active, not recruiting	40 Years	60 Years	All	10	Phase 2/Phase 3	Egypt
3	NCT00431119 (ClinicalTrials.gov)	October 1997	2/2/2007	Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid	A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid	Bullous Pemphigoid	Drug: Azathioprine or Mycophenolate mofetil	University Hospital Muenster	Hoffmann-La Roche	Completed	18 Years	90 Years	Both	70	Phase 2	Germany